Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3538-3543

  Takashima, K ^a   Miyake, H ^a   Furuta, R A ^a   Fujisawa, J I ^a   Iizawa, Y ^a   Kanzaki, N ^a   Shiraishi, M ^a   Okonogi, K ^a   Baba, M ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS REPLICATION;

AMIDES; ANTI-HIV AGENTS; GENE PRODUCTS, TAT; HELA CELLS; HIV-1; HUMANS; MEMBRANE FUSION; QUATERNARY AMMONIUM COMPOUNDS; RANTES; RECEPTORS, CCR5; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 0035180230     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3538-3543.2001     Document Type: Article

References (27)

1. CC chemokine receptor 5-mediated signaling and HIV-1 coreceptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion
2. CC CKR5: A RANTES, MIP-lα, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
3. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV Type 1
4. A small-molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
5. HIV-l-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor
6. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
7. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
8. Antiretroviral therapy in adults: Updated recommendations of the international AIDS society-USA panel
9. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection
10. The ß-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
11. + T cells
12. Identification of a major co-receptor for primary isolates of HIV-1
13. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
14. + cells is mediated by the chemokine receptor CC-CKR-5
15. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
16. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane. G protein-coupled receptor
17. - T cells provides a mechanism for lifelong persistence of HIV- 1, even in patients on effective combination therapy
18. Capture of an early fusion-active conformation of HIV-1 gp41
19. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
20. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
21. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
22. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation
23. The CXC chemokine SDF1 is the ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1
24. Cell-celi fusion assay to study role of chemokine receptors in human immunodeficiency virus type I entry
25. The second extracellular loop of CCR5 is the major determinant of ligand specificity
26. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety
27. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding